1-3 of 3
Jérôme Tiollier
Close
Sort by
Journal Articles

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Don M. Benson, Jr, Craig C. Hofmeister, Swaminathan Padmanabhan, Attaya Suvannasankha, Sundar Jagannath, Rafat Abonour, Courtney Bakan, Pascale Andre, Yvonne Efebera, Jérôme Tiollier, Michael A. Caligiuri, Sherif S. Farag
Journal: Blood
Blood (2012) 120 (22): 4324–4333.
https://doi.org/10.1182/blood-2012-06-438028
Published: 2012
Journal Articles

A Phase I Study of the Anti-Natural Killer Inhibitory Receptor (KIR) Monoclonal Antibody (1-7F9, IPH2101) in Elderly Patients with Acute Myeloid Leukemia (AML): Clinical and Immunological Effects of a Single Dose Followed by Repeated Dosing.

Norbert Vey, Jean-Henri Bourhis, MD, PhD, Herve Dombret, MD, PhD, Dominique Bordessoule, Thomas Prébet, MD, Aude Charbonnier, Stephane de Botton, Nicolas Boissel, MD, PhD, Christine d'Arnoux, MD, Francois Romagne, PhD, Pascale Andre, PhD, Jerome Tiollier, Patrick Squiban, Didier Blaise, Daniel Olive, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 632.
https://doi.org/10.1182/blood.V114.22.632.632
Published: 2009
Journal Articles

Enhancing Lysis of B Cell Lymphoma by Innovative γδ T Cell Immunotherapies Using Agonist IPH1101 (Phosphostim, BrHPP).

Jean-Francois Rossi, PhD, MD, Julie Gertner, Helene Sicard, PhD, Guy Laurent PhD, MD, Sylvie Lafaye de Micheaux, MD, Jerome Tiollier, PhD, Jean-Jacques Fournie, PhD, Patrick Squiban, MD, Volker Kunzmann PhD, MD
Journal: Blood
Blood (2006) 108 (11): 5201.
https://doi.org/10.1182/blood.V108.11.5201.5201
Published: 2006